$TOVX

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

GlobeNewswire Inc. · 6/11/2026, 12:00:00 PM

Theriva Biologics reported Phase 1 trial results for VCN-01, an oncolytic adenovirus combined with durvalumab, in immunotherapy-refractory head and neck squamous cell carcinoma patients. The study demonstrated prolonged overall survival (15.5-17.3 months depending on dosing arm) and biomarker evidence supporting VCN-01's stroma-degrading and immune-enhancing mechanisms. Results were published in Clinical Cancer Research journal.

Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026

GlobeNewswire Inc. · 4/18/2026, 5:17:00 PM

Theriva Biologics announced upcoming presentation of additional data from the VIRAGE Phase 2b clinical trial of VCN-01 at the AACR 2026 Annual Meeting. The tumor response, biomarker, and subgroup analyses support an immune-mediated mechanism of action and demonstrate improved patient outcomes, including in patients with hepatic metastases. The company has reached agreement with FDA and EMA on a Phase 3 pivotal trial design for VCN-01 combined with gemcitabina/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer.

$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum

GlobeNewswire Inc. · 2/19/2026, 4:00:00 PM

Small- and mid-cap stocks are gaining momentum on execution milestones and transformative deals. Interactive Strength surged 40% after acquiring Ergatta to boost revenue guidance by 50%. Kraig Biocraft Laboratories activated its 2026 production program for spider silk manufacturing. Theriva Biologics out-licensed an asset to focus on its pancreatic cancer program, while PMGC Holdings' subsidiary filed patents for animal health applications.

Theriva™ Biologics anuncia la próxima presentación de los datos del ensayo clínico de Fase 1 del VCN-01 para el retinoblastoma en el Congreso de la Academia de Oftalmología de Asia-Pacífico (APAO) de 2026

GlobeNewswire Inc. · 2/3/2026, 1:00:00 PM

Theriva Biologics announced that clinical and safety results from a Phase 1 study of VCN-01 (zabilugene almadenorepvec) for refractory retinoblastoma will be presented at the 41st Asia-Pacific Academy of Ophthalmology Congress in Hong Kong on February 7, 2026. The presentation will include preclinical data demonstrating synergistic antitumor activity when combining topotecan with VCN-01, potentially improving outcomes for patients with difficult-to-treat vitreous seeding.

Theriva™ Biologics anuncia el asesoramiento científico favorable de la Agencia Europea de Medicamentos (EMA) sobre el diseño de un ensayo de fase III de VCN-01 en el adenocarcinoma ductal pancreático (ACDP) metastásico

GlobeNewswire Inc. · 12/29/2025, 1:00:00 PM

Theriva Biologics received favorable scientific advice from the European Medicines Agency (EMA) on the design of a Phase 3 clinical trial for VCN-01 in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma (PDAC). The EMA approved the proposed trial design, sample size, and adaptive design elements. The company plans to meet with the FDA in H1 2026 for a multinational Phase 3 trial and has cash runway through Q1 2027.